Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SLDB 
Solid Biosciences LLC (SLDB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SLDB (1-star) is a SELL. SELL since 2 days. Profits (-38.33%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 44.8% | Avg. Invested days 36 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 266.96M USD | Price to earnings Ratio - | 1Y Target Price 16.7 |
Price to earnings Ratio - | 1Y Target Price 16.7 | ||
Volume (30-day avg) 1814919 | Beta 1.98 | 52 Weeks Range 2.88 - 12.95 | Updated Date 04/1/2025 |
52 Weeks Range 2.88 - 12.95 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.06 |
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate -0.7822 | Actual -1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.86% | Return on Equity (TTM) -94.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 142220240 | Price to Sales(TTM) 3.65 |
Enterprise Value 142220240 | Price to Sales(TTM) 3.65 | ||
Enterprise Value to Revenue 1.16 | Enterprise Value to EBITDA -3.69 | Shares Outstanding 77493000 | Shares Floating 39274207 |
Shares Outstanding 77493000 | Shares Floating 39274207 | ||
Percent Insiders 0.7 | Percent Institutions 62.23 |
Analyst Ratings
Rating 4.58 | Target Price 16.9 | Buy 5 | Strong Buy 7 |
Buy 5 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Solid Biosciences LLC
Company Overview
History and Background
Solid Biosciences LLC (SLDB) was founded in 2013 and is focused on developing gene therapies for Duchenne muscular dystrophy (DMD). It has faced clinical trial setbacks but continues to pursue its mission.
Core Business Areas
- Gene Therapy Development: Solid Biosciences focuses primarily on developing gene therapies to treat Duchenne Muscular Dystrophy (DMD).
Leadership and Structure
Ilan Ganot serves as the CEO. The company has a board of directors and operates with a functional structure focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- SGT-001 (formerly AAV-DYSF): SGT-001 is Solid Biosciences' lead product candidate, an adeno-associated virus (AAV) vector-mediated gene therapy designed to deliver a functional dystrophin gene to patients with DMD. The therapy has faced clinical holds and safety concerns. As an investigational product, SGT-001 does not generate revenue currently. Competitors include Sarepta Therapeutics (SRP) and BioMarin (BMRN) in the DMD gene therapy space.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly evolving, with significant investment and regulatory scrutiny. There is a high unmet need for effective treatments for rare genetic diseases like DMD.
Positioning
Solid Biosciences is a key player in the DMD gene therapy space, but it faces stiff competition and has experienced setbacks. Its competitive advantage lies in its specific gene therapy construct and delivery methods, though this is countered by the risks inherent in unproven novel therapies.
Total Addressable Market (TAM)
The global DMD market is projected to reach billions of dollars. Solid Biosciences' TAM depends on the success of SGT-001 and its ability to capture market share from competitors. It is still in clinical development, its current TAM position is speculative.
Upturn SWOT Analysis
Strengths
- Specialized focus on DMD
- Proprietary AAV vector technology
- Strong scientific team
Weaknesses
- Clinical trial setbacks and holds
- High cash burn rate
- Reliance on a single lead product candidate
- Limited revenue stream
Opportunities
- Potential for breakthrough therapy designation
- Partnerships with larger pharmaceutical companies
- Expansion of gene therapy platform to other diseases
- Positive clinical trial data
Threats
- Regulatory hurdles
- Competition from other gene therapy companies
- Adverse events in clinical trials
- Failure to obtain regulatory approval
- Efficacy of competing treatments
Competitors and Market Share
Key Competitors
- SRP
- BMRN
- PTCT
Competitive Landscape
Solid Biosciences faces intense competition from larger, more established companies like Sarepta and BioMarin, which have approved DMD therapies. Solid's primary advantage lies in its differentiated gene therapy approach, but it must overcome safety and efficacy hurdles.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Solid Biosciences' growth is primarily reflected in its pipeline development, not revenue. Stock price correlated with news regarding its gene therapy candidates.
Future Projections: Future growth hinges on successful clinical trials and regulatory approval for SGT-001. Analyst projections are contingent upon these events.
Recent Initiatives: Recent initiatives include modifications to the SGT-001 clinical trial protocol and efforts to address safety concerns.
Summary
Solid Biosciences is a high-risk, high-reward biotech company focused on DMD gene therapy. Clinical trial challenges have created volatility. Success depends on achieving positive clinical data and regulatory approval and having enough cash to make it to the approval and manufacturing process.
Similar Companies
BMRN
Biomarin Pharmaceutical Inc
BMRN
Biomarin Pharmaceutical Inc
PTCT
PTC Therapeutics Inc
PTCT
PTC Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Solid Biosciences SEC Filings
- Industry Reports
- Analyst Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is estimated and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Solid Biosciences LLC
Exchange NASDAQ | Headquaters Charlestown, MA, United States | ||
IPO Launch date 2018-01-26 | President, CEO & Director Mr. Alexander G. Cumbo | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.solidbio.com |
Full time employees 100 | Website https://www.solidbio.com | ||
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy; SGT-212 for the treatment of Friedreich's ataxia that is in phase 1/2; SGT-501 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia that is in preclinical phase; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene, which is in preclinical phase; It is also developing SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries, genetic regulators, such as promoters, UTRs, and introns, immunomodulation technologies, manufacturing purity, and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.